Ibsrela

Irritable Bowel Syndrome with Constipation

Ibsrela is specifically indicated for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a chronic gastrointestinal disorder characterized by frequent abdominal pain and difficult, infrequent, or incomplete bowel movements.

The medication is used to help manage the primary symptoms of IBS-C, which include:

• Abdominal pain and discomfort.
• Bloating.
• Hard or lumpy stools.
• Straining during bowel movements.
• Infrequent bowel movements.

Ibsrela is intended for use only in adults. It is not approved for use in pediatric patients. It is strictly avoided in children under the age of 6 due to the risk of severe dehydration, and its safety and effectiveness have not been established in patients under the age of 18.

Mechanism of Action

Ibsrela contains the active ingredient tenapanor, which belongs to a class of medications called sodium-hydrogen exchanger 3 (NHE3) inhibitors. Unlike many other medications, it acts locally within the gastrointestinal tract and is not significantly absorbed into the bloodstream.

How It Relieves Constipation

The medication works by blocking the NHE3 transporter, a protein found on the surface of the small intestine and colon. This protein is responsible for absorbing sodium from the gut. When this process is blocked:

• Sodium remains inside the intestines instead of being absorbed.
• The presence of extra sodium causes water to move into the intestines through a process called osmosis.
• The increased water content softens the stool and adds bulk, which helps the stool move through the digestive system more quickly and frequently.

How It Relieves Pain

In addition to its effects on bowel movements, Ibsrela is thought to help reduce abdominal pain. It may do this by decreasing the sensitivity of the nerves in the gut that transmit pain signals. This helps lower the overall discomfort often experienced by people with irritable bowel syndrome with constipation (IBS-C).

Common Side Effects

The most frequently reported side effect of Ibsrela is diarrhea. Other common side effects may include:

• Abdominal pain or bloating
• Gas (flatulence)
• Dizziness
• Rectal bleeding

Serious Side Effects

In some cases, Ibsrela can cause serious side effects that require immediate medical attention. These include:

• Severe diarrhea: This is the most common serious side effect and can lead to significant fluid loss and dehydration.
• Dehydration: Signs may include decreased urination, dark-colored urine, extreme thirst, dry mouth, or feeling lightheaded.
• Severe stomach area pain: New or worsening abdominal discomfort should be reported to a doctor.

If you experience severe diarrhea, your healthcare provider may advise you to stop taking the medication and increase your fluid intake to prevent complications.

Boxed Warning: Pediatric Risk

Ibsrela is contraindicated in children younger than 6 years of age. In animal studies, the active ingredient caused severe dehydration that led to death. Because of the risk of serious dehydration, healthcare providers also avoid prescribing this medication to patients aged 6 years to less than 18 years. The safety and effectiveness of Ibsrela have not been established in any pediatric patient population.

Gastrointestinal Obstruction

This medication must not be used by individuals who have a known or suspected mechanical gastrointestinal obstruction. This refers to a physical blockage in the bowels that prevents the normal passage of waste.

Severe Diarrhea

Diarrhea is the most common side effect associated with Ibsrela and can sometimes become severe. If severe diarrhea occurs, it may lead to significant fluid loss and dehydration. Most reports of diarrhea occur within the first two weeks of starting treatment. If diarrhea becomes unmanageable, a healthcare provider may recommend stopping the medication and starting fluid replacement therapy.

Pregnancy and Breastfeeding

Ibsrela is minimally absorbed into the bloodstream after being taken by mouth, which suggests that exposure to a fetus is likely to be low. However, individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits with their doctor. It is currently unknown if the medication passes into human breast milk, though the low absorption levels suggest minimal exposure to a nursing infant.

Pregnancy

There is currently limited data on the use of Ibsrela during pregnancy. Because the medication is minimally absorbed into the bloodstream from the digestive tract, it is unlikely that a developing fetus would be exposed to the drug. Research in animals using doses much higher than the recommended human dose did not show evidence of harm to the fetus. Pregnant individuals should discuss the potential risks and benefits of treatment with their healthcare provider.

Breastfeeding

It is unknown whether Ibsrela is present in human breast milk or if it has any effect on a nursing infant or milk production. Since the drug is not well-absorbed into the body, exposure to a breastfed infant is expected to be very low. Patients are encouraged to talk with their healthcare provider about the use of this medication while breastfeeding to determine the best course of action for both the parent and the child.

Dosage Forms

Ibsrela is supplied in the following form:

• Oral Tablet: This medication is a film-coated tablet intended for oral administration.

The tablets are packaged in bottles that include a desiccant canister to protect the medicine from moisture. It is recommended to keep the tablets in their original container with the desiccant and to keep the bottle tightly closed.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Ibsrela (tenapanor) in September 2019. It is specifically indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adult patients.

Boxed Warning

Ibsrela carries a Boxed Warning, the FDA’s most serious category of warning, due to the risk of severe dehydration in pediatric patients. The following restrictions apply:

• Contraindication: Ibsrela is contraindicated in children under the age of 6 years. In clinical studies involving young rats (standardized to human age equivalents), the medication caused deaths related to dehydration.
• Avoidance in Older Children: The FDA recommends avoiding the use of Ibsrela in patients aged 6 years to less than 18 years, as the safety and effectiveness of the drug have not been established for this age group.

Regulatory Status

Ibsrela is a prescription-only medication and is not available over-the-counter. It is classified as a sodium-hydrogen exchanger 3 (NHE3) inhibitor. The FDA has not approved this medication for use in children or for any conditions other than IBS-C.

Insurance Coverage

The amount you pay for Ibsrela depends largely on your health insurance plan. Many insurance providers require prior authorization, which means your doctor must provide additional information to the insurance company before the drug is covered. Your specific co-pay or co-insurance will depend on your plan's formulary tier for this medication.

Retail Price

For those paying out-of-pocket, the retail price for a standard 30-day supply of 50 mg tablets is approximately $1,800. Prices can vary between different retail and mail-order pharmacies.

Financial Assistance Programs

There are options available to help manage the cost of Ibsrela:

• Savings Cards: The manufacturer may provide a savings card for patients with commercial insurance to help lower monthly co-pays.
• Patient Assistance: Programs may be available for individuals who are uninsured or meet specific financial criteria to receive the medication at a lower cost.

Patients are encouraged to contact their insurance provider or the manufacturer's support program to determine their specific costs and eligibility for financial aid.